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Despite years of research and hundreds of reports on tumour markers in oncology, the number of markers that have emerged as
clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same
or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we
attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodological
problems have been cited to explain these discrepancies. Unfortunately, many tumour marker studies have not been reported in a
rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or
the generalisability of the study results. The development of guidelines for the reporting of tumour marker studies was a major
recommendation of the US National Cancer Institute and the European Organisation for Research and Treatment of Cancer
(NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. Similar to the successful CONSORT initiative for
randomised trials and the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the
study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition,
the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to
encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the
usefulness of the data and understand the context in which the conclusions apply.
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Despite years of research and hundreds of reports on tumour
markers in oncology, the number of markers that have emerged as
clinically useful is pitifully small (Hayes et al, 1996; Bast et al, 2001;
Schilsky and Taube, 2002). Often initially reported studies of a
marker show great promise, but subsequent studies on the same or
related markers yield inconsistent conclusions or stand in direct
contradiction to the promising results. It is imperative that we
attempt to understand the reasons that multiple studies of the
same marker lead to differing conclusions. A variety of problems
have been cited to explain these discrepancies, such as general
methodological differences, poor study design, assays that are not
standardised or lack reproducibility, and inappropriate or
misleading statistical analyses often based on sample sizes too
small to draw meaningful conclusions (McGuire, 1991; Fielding
et al, 1992; Burke and Henson, 1993; Concato et al, 1993; Gasparini
et al, 1993; Simon and Altman, 1994; Gasparini, 1998; Hall and
Going, 1999). For example, in retrospective studies, patient
populations are often biased towards patients with available
tumour specimens. Specimen availability may be related to tumour
size and patient outcome (Hoppin et al, 2002), and the quantity,
quality, and preservation method of the specimen may affect
feasibility of conducting certain assays. There can also be biases or
large variability inherent in the assay results, depending on the
particular assay methods used (Thor et al, 1999; Gancberg et al,
2000; McShane et al, 2000; Paik et al, 2002; Roche et al, 2002).
Statistical problems are commonplace. These problems include
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www.bjcancer.comunderpowered studies or overly optimistic reporting of effect sizes
and significance levels due to multiple testing, subset analyses, and
cutpoint optimisation (Altman et al, 1995).
Unfortunately, many tumour marker studies have not been
reported in a rigorous fashion, and published articles often lack
sufficient information to allow adequate assessment of the quality
of the study or the generalisability of study results. Such reporting
deficiencies are increasingly being highlighted by systematic
reviews of the published literature on particular markers or
cancers (Brundage et al, 2002; Mirza et al, 2002; Riley et al,
2003a,b, 2004; Burton and Altman, 2004; Popat et al, 2004).
The development of guidelines for the reporting of tumour
marker studies was a major recommendation of the US National
Cancer Institute and the European Organisation for Research and
Treatment of Cancer (NCI-EORTC) First International Meeting on
Cancer Diagnostics (From Discovery to Clinical Practice: Diag-
nostic Innovation, Implementation, and Evaluation) that was
convened in Nyborg, Denmark in July 2000. The purpose of the
meeting was to discuss issues, accomplishments, and barriers in
the field of cancer diagnostics. Poor study design and analysis,
assay variability, and inadequate reporting of studies were
identified as some of the major barriers to progress in this field.
One of the working groups formed at the Nyborg meeting was
charged with addressing statistical issues of poor design and
analysis, and reporting of tumour marker prognostic studies. The
guidelines presented here are the product of that committee. The
Program for the Assessment of Clinical Cancer Tests (PACCT)
Strategy Group of the US National Cancer Institute has also
strongly endorsed this effort (http://www.cancerdiagnosis.nci.nih.
gov/assessment/).
The reporting guidelines proposed in this paper build upon
earlier suggestions (Altman and Lyman, 1998; Gion et al, 1999;
Altman, 2001a,b; Riley et al, 2003a) as well as educational
publications (McShane and Simon, 2001; Simon, 2001; Biganzoli
et al, 2003; Schumacher et al, 2005). They recommend elements
and formats for presentation with the objectives of facilitating
evaluation of the appropriateness and quality of study design,
methods, analyses, and improving the ability to compare results
across studies. Similar to the successful CONSORT initiative for
randomised clinical trials (Moher et al, 2001), and the STARD
statement for studies of diagnostic test accuracy (Bossuyt et al,
2003a), these guidelines suggest relevant information that should
be provided about the study design, preplanned hypotheses,
patient and specimen characteristics, assay methods, and statistical
analysis methods. In addition, the guidelines suggest helpful
presentations of data and important elements to include in
discussions. To be published separately, in an explanatory
document, are specific justifications for the need for each of the
elements of the recommendations.
We have developed these reporting guidelines primarily for
studies evaluating a single tumour marker of interest, often
including adjustment for standard clinical prognostic variables.
They are largely relevant for studies exploring more than one
marker, but they are not intended to specifically address statistical
considerations in development of prognostic models from very
large numbers of candidate markers. The reason we chose to
emphasise prognostic marker studies is that they represent a large
proportion of the tumour marker literature and tend to be
particularly fraught with problems because they are often
conducted on retrospective collections of specimens, and analyses
may contain substantial exploratory components. For purposes of
this paper, we define prognostic markers to be markers that have
an association with some clinical outcome, typically a time-to-
event outcome such as overall survival or recurrence-free survival.
(Some individuals adhere to a more strict definition of prognostic
marker as applying only to the natural history of patients who
received no treatment following local therapy.) Prognostic markers
may be considered in the clinical management of a patient. For
example, they may be used as decision aids in determining whether
a patient should receive adjuvant chemotherapy or how aggressive
that therapy should be. Predictive markers are generally used to
make more specific choices between treatment options. Predictive
markers are used as indicators of the likely benefit to a specific
patient of a specific treatment. For example, a predictive marker
might indicate that a patient expressing the marker will benefit
more from a new treatment compared to standard treatment,
whereas a patient not expressing the marker will derive little or no
benefit from the new treatment. Predictive marker studies usually
occur later in the marker development process and there are far
fewer published examples. Knowledge of specific treatments
received and how those treatment decisions were made become
even more critical. In our judgment, the issues in reporting
predictive marker studies are complex and different enough from
those of prognostic marker studies that we are not willing to claim
that these guidelines give predictive marker studies adequate
coverage, although we believe that most of the guidance is relevant
to such studies too.
The goal of these guidelines is to encourage transparent and
complete reporting so that the relevant information will be
available to others to help them to judge the usefulness of the
data and understand the context in which the conclusions apply.
These guidelines are not intended to dictate specific designs or
analysis strategies. In general, there is more than one acceptable
approach to the design or analysis of a particular study, although
these guidelines should help to eliminate some clearly unaccep-
table options as have been discussed in other papers (Concato
et al, 1993; Altman et al, 1994; Altman and Lyman, 1998;
Schumacher et al, 2005). For example, unacceptable options
include reporting statistical significance of a marker’s prognostic
effect without acknowledging that the significance testing was
preceded by extensive manipulations involving derivation of data-
dependent cutpoints or variable selection procedures. High-quality
reporting of a study cannot transform a poorly designed or
analysed study into a good one, but it can help to identify the poor
studies and we believe that it is an important first step in
improving the overall quality of tumour marker prognostic studies.
MATERIALS AND METHODS
Initial ideas for key elements to be addressed in the guidelines
were assembled from literature citing empirical evidence of
inadequate reporting or problematic analysis methods (Hilsenbeck
et al, 1992; Altman et al, 1994, 1995; Simon and Altman, 1994)
based on published reviews of tumour marker studies. Ideas were
also generated by reviewing similar reporting guidelines that have
been produced for other types of medical research studies
(CONSORT, QUOROM, MOOSE, STARD) (Moher et al, 1999,
2001; Stroup et al, 2000; Bossuyt et al, 2003a). Three individuals
from the working group (LM, DA, GC) wrote a first draft to serve
as a starting point for discussion by the full group. Comments on
drafts were made by the full group on a conference call and
through multiple e-mail exchanges. A very preliminary draft was
presented to the PACCT Strategy Group in January 2001. In
response to comments, the guidelines were shortened, reformatted,
and recirculated to the full committee. They were posted to
the PACCT website (http://www.cancerdiagnosis.nci.nih.gov/
assessment/progress/clinical.html) for public comment and circu-
lated to attendees of the NCI-EORTC Second International Meeting
on Cancer Diagnostics (Conference on the Development of New
Diagnostic Tools for Cancer) that was held in Washington, DC in
June 2002. In February 2003, three committee members (DA, LM,
WS) met for 2 days to make further revisions. The version
produced in that February meeting was sent to the full committee
for final comment. The version presented here incorporates those
final comments and was approved by the full committee.
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Table 1 shows the recommendations for reporting studies on
tumour markers. Specific items are grouped under headings:
Introduction, Materials and Methods, Results, and Discussion,
reflecting the relevant sections of a published scientific article.
Further details about the recommendations and explanatory
material will be provided in a separate article.
As noted in item 12, a diagram may be helpful to indicate
numbers of individuals included at different stages of a study. As
a minimum, such a diagram could show the number of patients
originally in the sample, the number remaining after exclusions,
and the numbers incorporated into univariate and multivariable
analyses.
DISCUSSION
The reporting guidelines presented here are the result of a
collaborative effort among statisticians, clinicians, and laboratory
scientists who are committed to improving and accelerating the
process by which tumour markers that provide useful information
for management of cancer patients are adopted into clinical
practice. In addition to the authors of this paper, we gratefully
acknowledge the contributions of many individuals with whom we
have had informal discussions regarding these guidelines and who
have been supportive of this effort. All of us participating in the
development of these guidelines are actively involved in the design,
conduct, and analysis of studies involving tumour markers.
Collectively, we serve as editors and reviewers for numerous
scientific journals that publish tumour marker studies, we serve on
programme committees for international meetings, as decision-
makers for funding agencies, participants in national and
international committees charged with evaluating and prioritising
tumour markers for further study or making recommendations
for clinical use, and are actively involved in our own research
involving tumour markers. As editors, reviewers, and programme
and advisory committee members, we have struggled with
having to make decisions when insufficient information is
provided about study design or analysis methods. As individual
investigators, we have experienced the frustration of trying to
interpret often confusing literature to guide our own research
programmes.
Table 1 REporting recommendations for tumour MARKer prognostic studies (REMARK)
Introduction
1. State the marker examined, the study objectives, and any prespecified hypotheses.
Materials and Methods
Patients
2. Describe the characteristics (e.g. disease stage or comorbidities) of the study patients, including their source and inclusion and exclusion criteria.
3. Describe treatments received and how chosen (e.g. randomised or rule-based).
Specimen characteristics
4. Describe type of biological material used (including control samples), and methods of preservation and storage.
Assay methods
5. Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits used, quality control procedures, reproducibility
assessments, quantitation methods, and scoring and reporting protocols. Specify whether and how assays were performed blinded to the study end point.
Study design
6. State the method of case selection, including whether prospective or retrospective and whether stratification or matching (e.g. by stage of disease or age) was
employed. Specify the time period from which cases were taken, the end of the follow-up period, and the median follow-up time.
7. Precisely define all clinical end points examined.
8. List all candidate variables initially examined or considered for inclusion in models.
9. Give rationale for sample size; if the study was designed to detect a specified effect size, give the target power and effect size.
Statistical analysis methods
10. Specify all statistical methods, including details of any variable selection procedures and other model-building issues, how model assumptions were verified, and
how missing data were handled.
11. Clarify how marker values were handled in the analyses; if relevant, describe methods used for cutpoint determination.
Results
Data
12. Describe the flow of patients through the study, including the number of patients included in each stage of the analysis (a diagram may be helpful) and reasons for
dropout. Specifically, both overall and for each subgroup extensively examined report the numbers of patients and the number of events.
13. Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) prognostic variables, and tumour marker, including
numbers of missing values.
Analysis and presentation
14. Show the relation of the marker to standard prognostic variables.
15. Present univariate analyses showing the relation between the marker and outcome, with the estimated effect (e.g. hazard ratio and survival probability). Preferably
provide similar analyses for all other variables being analysed. For the effect of a tumour marker on a time-to-event outcome, a Kaplan–Meier plot is
recommended.
16. For key multivariable analyses, report estimated effects (e.g. hazard ratio) with confidence intervals for the marker and, at least for the final model, all other variables
in the model.
17. Among reported results, provide estimated effects with confidence intervals from an analysis in which the marker and standard prognostic variables are included,
regardless of their significance.
18. If done, report results of further investigations, such as checking assumptions, sensitivity analyses, internal validation.
Discussion
19. Interpret the results in the context of the prespecified hypotheses and other relevant studies; include a discussion of limitations of the study.
20. Discuss implications for future research and clinical value.
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community as a whole. Poorly designed or inappropriately
analysed studies can attract undeserved attention when they
produce very dramatic, but unfortunately incorrect results. In
contrast, some carefully designed and analysed studies have
been overlooked because they produced less dramatic, but
perhaps more accurate and realistic results. The poor quality of
reporting of prognostic marker studies may have contributed
to the relative scarcity of markers whose prognostic influence is
well-supported. Thorough reporting is required no matter what
methods of design and analysis are used. Thorough reporting does
not solve problems of poor design or analysis that are being
reported; rather, it just fairly describes what problems may exist
and need to be considered in interpretation. It is our hope that
these guidelines will be embraced and used by journal editors,
reviewers, funding agencies, decision-making bodies, and indivi-
dual investigators.
These guidelines have been labelled as applying to clinical
prognostic studies. Not all of the elements apply to studies
conducted in earlier phases of marker development (Hammond
and Taube, 2002), for example early marker studies seeking to
correlate a new marker with other clinical variables or existing
prognostic factors. However, our recommendation is that inves-
tigators conducting early marker studies should strive to adhere to
as many of the reporting guidelines as applicable in their situation,
and the guidelines might also suggest issues that will be important
for them to consider in planning follow-up studies on their
investigational markers. Studies of markers that can be used to
predict the success of particular therapies, such as molecular-
targeted therapies, need additional considerations. It is our
opinion that predictive marker studies should generally be
conducted within randomised trials, require a sufficient (usually
larger) effective sample size, and assays should be in a more
advanced state of development. The CONSORT statement for
randomised clinical trials can serve as a starting point for
reporting guidelines for predictive marker studies, but additional
issues relating to the marker assays must be addressed. It is our
feeling that more stringent and specific guidelines need to be
developed for reporting studies of predictive markers. Such studies
will be considered in somewhat more detail in the planned
explanatory paper.
It may not be possible to report every detail for every study. For
example, it is often difficult to provide detailed patient inclusion/
exclusion criteria or treatment information in retrospective
prognostic marker studies using archived tumour specimens.
The impact of such missing information must be judged in the
specific context of the study and its stated conclusions. For
example, a ‘pure’ prognostic study should be conducted in a group
of patients who have not received any systemic adjuvant therapy,
but treatment information is often missing or unreliable in
retrospective studies. In these cases, it is important to recognise
that apparent ‘prognostic’ effects may be influenced by potential
treatment by marker interactions. The key point is that there must
be a clear statement of what is and what is not known. In addition,
it was beyond the scope of these guidelines to recommend specific
details that should be reported for each of the major classes of
marker assays, for example, immunohistochemistry, in situ
hybridisation methods, or DNA-based assays. There is an ongoing
effort to define such assay-specific checklists by another working
group evolving from the NCI-EORTC International Meetings on
Cancer Diagnostics.
Some of the reviewers suggested that the guidelines should
promote full public access to data, possibly even individual-level
data. We have chosen not to include this issue in the current
scope of the guidelines even though we view movement in this
direction as generally positive. One concern is that if a study was
poorly designed or inadequately reported, making its data
publicly available may simply propagate bad science. Good
study design and data quality have to come first. We do recog-
nise the potential benefits of promoting full public access to
good quality data. It would allow verification of published ana-
lysis methods and results and would facilitate alternative ana-
lyses and meta-analyses. Attainment of these goals would be
helped significantly if guidelines 10 and 11 were strictly applied,
so that statistical analysis methods were described in suffi-
cient detail to allow an individual independent of the original
research team to reproduce the results of the study if supplied
with the raw data. For extensive analyses, it is possible that
some of this information would have to be provided as
supplementary material available outside of the main published
report, for example, on the journal’s or author’s website.
While some might view adherence to these guidelines as
yet another burden in trying to publish or obtain funding, we
would argue that use of these guidelines is more likely to reduce
burdens on the research community. Making clear what is
considered relevant and important to report in journal articles
or funding proposals will likely reduce review time, reduce
requests for revisions, and help to ensure a fair review process.
Furthermore, we consider it as a prerequisite for a thoughtful
presentation and interpretation of the results of a specific study
and a key aid for a summary assessment of the effect of a marker in
a review paper. Most importantly, what greater reduction in
burden could there be than to eliminate some of the false leads
generated by poorly designed, analysed, or reported studies which
send researchers down unproductive paths, wasting years of time
and money?
The ultimate usefulness of these guidelines will rely on
how widely they are adopted. We are heartened by the enthu-
siastic responses we received from the several journals who
have agreed to simultaneously publish this paper. There is a
clear recognition in the community that the time has come (if
not long overdue) to improve the quality of tumour marker
study reporting and conduct. We hope that many journals
will adopt these guidelines as part of their editorial require-
ments. To the extent that does not happen immediately, we
have to rely on authors of journal articles and reviewers of
those articles to initiate the movement toward adherence to these
guidelines.
We expect that just as tumour marker research will evolve, these
guidelines will have to evolve to address new study paradigms and
new assay technologies. It is our hope that publication of these
guidelines will generate vigorous discussion leading to continually
improved versions and ultimately to improved quality of tumour
marker studies.
The guidelines presented in this paper are available at http://
www.cancerdiagnosis.nci.nih.gov/assessment/progress/clinical.
html, as will be other recommendations from the group in
due course. As noted, a detailed explanatory paper is in
preparation, following the model of similar articles relating to
the CONSORT and STARD statements (Altman et al, 2001;
Bossuyt et al, 2003b).
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